Cargando…

Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis

BACKGROUND: The existing evidence indicates increased levels of transforming growth factor beta 1 (TGF-β1) in patients with type 2 diabetes mellitus (T2DM) and those with type 2 diabetic nephropathy (T2DN); yet no meta-analysis displays a reliable result. Here we conducted a meta-analysis to evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Yong-Chao, Chen, Yin-Ling, Pan, Yan-Hong, Ling, Wei, Tian, Fang, Zhang, Xiao-Xi, Zhao, Hai-Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403085/
https://www.ncbi.nlm.nih.gov/pubmed/28403088
http://dx.doi.org/10.1097/MD.0000000000006583
_version_ 1783231367134314496
author Qiao, Yong-Chao
Chen, Yin-Ling
Pan, Yan-Hong
Ling, Wei
Tian, Fang
Zhang, Xiao-Xi
Zhao, Hai-Lu
author_facet Qiao, Yong-Chao
Chen, Yin-Ling
Pan, Yan-Hong
Ling, Wei
Tian, Fang
Zhang, Xiao-Xi
Zhao, Hai-Lu
author_sort Qiao, Yong-Chao
collection PubMed
description BACKGROUND: The existing evidence indicates increased levels of transforming growth factor beta 1 (TGF-β1) in patients with type 2 diabetes mellitus (T2DM) and those with type 2 diabetic nephropathy (T2DN); yet no meta-analysis displays a reliable result. Here we conducted a meta-analysis to evaluate characteristic changes of TGF-β1 in T2DM and diabetic nephropathy. METHODS: A systematic search was conducted for eligible studies, which reported the association of TGF-β1 withT2DM and T2DN patients, in PubMed, Wangfang, Chinese-Cqvip, and China National Knowledge Infrastructure database, from February 1, 1991 to December 15, 2015. The association of serum and urine TGF-β1 in T2DM and T2DN patients should be evaluated in case-control studies. The Newcastle-Ottawa Scale was used to access the quality of the included studies, and pooling data were synthesized as standard mean difference (SMD) and 95% confidence interval (CI). The collected data were synthesized according to Cochrane Handbook for Systematic Reviews criteria. Subgroup analysis was conducted by albuminuria and ethnicity. Regression analysis and sensitivity analysis were used to explore the sources of heterogeneity. Publication bias was judged by the Egger test. RESULTS: Sixty-three case-control studies of 364 T2DM patients (1604 T2DN patients) and 2100 healthy controls were included for meta-analysis. Compared with the controls, the cases had increased TGF-β1 levels in both serum (T2DM: SMD 1.78 μg/L; 95% CI 0.98–2.59, P < .001; T2DN: SMD 4.70 μg/L, 95% CI 3.55–5.85, P < .001) and urine samples (T2DM: SMD 1.27 pg/mg.creatinine, 95% CI 0.16–2.38, P < .001; SMD 1.19 ng/L, 95% CI 0.77–1.62, P < .001; T2DN: SMD 3.14 pg/mg.creatinine, 95% CI 2.15–4.13, P < .001; SMD 4.50 ng/L, 95% CI 3.16–5.83, P < .001). The increase of serum TGF-β1 persisted in patients with either microalbuminuria or macroalbuminuria (all P < .001) in Chinese and non-Chinese population. High heterogeneity exists in some comparisons and small-sample studies. CONCLUSIONS: Patients with T2DM and those with albuminuria, Chinese or non-Chinese, had increased serum and urine TGF-β1 levels.
format Online
Article
Text
id pubmed-5403085
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-54030852017-04-28 Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis Qiao, Yong-Chao Chen, Yin-Ling Pan, Yan-Hong Ling, Wei Tian, Fang Zhang, Xiao-Xi Zhao, Hai-Lu Medicine (Baltimore) 4300 BACKGROUND: The existing evidence indicates increased levels of transforming growth factor beta 1 (TGF-β1) in patients with type 2 diabetes mellitus (T2DM) and those with type 2 diabetic nephropathy (T2DN); yet no meta-analysis displays a reliable result. Here we conducted a meta-analysis to evaluate characteristic changes of TGF-β1 in T2DM and diabetic nephropathy. METHODS: A systematic search was conducted for eligible studies, which reported the association of TGF-β1 withT2DM and T2DN patients, in PubMed, Wangfang, Chinese-Cqvip, and China National Knowledge Infrastructure database, from February 1, 1991 to December 15, 2015. The association of serum and urine TGF-β1 in T2DM and T2DN patients should be evaluated in case-control studies. The Newcastle-Ottawa Scale was used to access the quality of the included studies, and pooling data were synthesized as standard mean difference (SMD) and 95% confidence interval (CI). The collected data were synthesized according to Cochrane Handbook for Systematic Reviews criteria. Subgroup analysis was conducted by albuminuria and ethnicity. Regression analysis and sensitivity analysis were used to explore the sources of heterogeneity. Publication bias was judged by the Egger test. RESULTS: Sixty-three case-control studies of 364 T2DM patients (1604 T2DN patients) and 2100 healthy controls were included for meta-analysis. Compared with the controls, the cases had increased TGF-β1 levels in both serum (T2DM: SMD 1.78 μg/L; 95% CI 0.98–2.59, P < .001; T2DN: SMD 4.70 μg/L, 95% CI 3.55–5.85, P < .001) and urine samples (T2DM: SMD 1.27 pg/mg.creatinine, 95% CI 0.16–2.38, P < .001; SMD 1.19 ng/L, 95% CI 0.77–1.62, P < .001; T2DN: SMD 3.14 pg/mg.creatinine, 95% CI 2.15–4.13, P < .001; SMD 4.50 ng/L, 95% CI 3.16–5.83, P < .001). The increase of serum TGF-β1 persisted in patients with either microalbuminuria or macroalbuminuria (all P < .001) in Chinese and non-Chinese population. High heterogeneity exists in some comparisons and small-sample studies. CONCLUSIONS: Patients with T2DM and those with albuminuria, Chinese or non-Chinese, had increased serum and urine TGF-β1 levels. Wolters Kluwer Health 2017-04-14 /pmc/articles/PMC5403085/ /pubmed/28403088 http://dx.doi.org/10.1097/MD.0000000000006583 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0
spellingShingle 4300
Qiao, Yong-Chao
Chen, Yin-Ling
Pan, Yan-Hong
Ling, Wei
Tian, Fang
Zhang, Xiao-Xi
Zhao, Hai-Lu
Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis
title Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis
title_full Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis
title_fullStr Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis
title_full_unstemmed Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis
title_short Changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis
title_sort changes of transforming growth factor beta 1 in patients with type 2 diabetes and diabetic nephropathy: a prisma-compliant systematic review and meta-analysis
topic 4300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403085/
https://www.ncbi.nlm.nih.gov/pubmed/28403088
http://dx.doi.org/10.1097/MD.0000000000006583
work_keys_str_mv AT qiaoyongchao changesoftransforminggrowthfactorbeta1inpatientswithtype2diabetesanddiabeticnephropathyaprismacompliantsystematicreviewandmetaanalysis
AT chenyinling changesoftransforminggrowthfactorbeta1inpatientswithtype2diabetesanddiabeticnephropathyaprismacompliantsystematicreviewandmetaanalysis
AT panyanhong changesoftransforminggrowthfactorbeta1inpatientswithtype2diabetesanddiabeticnephropathyaprismacompliantsystematicreviewandmetaanalysis
AT lingwei changesoftransforminggrowthfactorbeta1inpatientswithtype2diabetesanddiabeticnephropathyaprismacompliantsystematicreviewandmetaanalysis
AT tianfang changesoftransforminggrowthfactorbeta1inpatientswithtype2diabetesanddiabeticnephropathyaprismacompliantsystematicreviewandmetaanalysis
AT zhangxiaoxi changesoftransforminggrowthfactorbeta1inpatientswithtype2diabetesanddiabeticnephropathyaprismacompliantsystematicreviewandmetaanalysis
AT zhaohailu changesoftransforminggrowthfactorbeta1inpatientswithtype2diabetesanddiabeticnephropathyaprismacompliantsystematicreviewandmetaanalysis